Percent Body Fat Change in Chinese Women After Adjuvant Chemotherapy for Breast Cancer
نویسندگان
چکیده
منابع مشابه
Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?
Background: The primary objective of this study was to assess BMD change in Iranian females with breast cancer. Methods: A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spin...
متن کاملAdjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
BACKGROUND Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. METHODS We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy ...
متن کاملDoes adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?
BACKGROUND The primary objective of this study was to assess BMD change in Iranian females with breast cancer. METHODS A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spine, ...
متن کاملIllness perception of breast cancer in affected women undergoing chemotherapy
Abstract Background: The aim of this study was to investigate the various aspects of illness perceptions about breast cancer in affected patients. Methods: A cross-sectional study enrolled 140 patients with breast cancer in their chemotherapy period within 14 months. The revised Illness Perception Questionnaire (revised IPQ) was used to assess the disease representations of breast cancer. The ...
متن کاملTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. METHODS This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Science Monitor
سال: 2018
ISSN: 1643-3750
DOI: 10.12659/msm.911423